Syngen Biotech Co.,Ltd.

Total Valuation

Syngen Biotech Co.,Ltd. carries a market capitalization of 2.38B, placing it among publicly traded companies globally. Its enterprise value stands at 3.75B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Syngen Biotech Co.,Ltd. currently has 27.10M shares outstanding.

Valuation Ratios

Syngen Biotech Co.,Ltd. trades at a trailing price-to-earnings ratio of 12.70. The price-to-sales ratio is 1.67, and the price-to-book ratio stands at 2.49.

Enterprise Valuation

On an enterprise value basis, Syngen Biotech Co.,Ltd. trades at an EV/EBITDA multiple of 10.72 and an EV/FCF ratio of 8.34. The EV/Sales ratio of 1.76 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.72 provides insight into valuation relative to core operating earnings.

Financial Position

Syngen Biotech Co.,Ltd. maintains a current ratio of 1.75, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.65, indicating elevated leverage, while an interest coverage ratio of 46.76 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Syngen Biotech Co.,Ltd. posts a return on equity of 20.48 and a return on invested capital of 10.27.

Taxes

Over the trailing twelve months, Syngen Biotech Co.,Ltd. has paid 68.84M in income taxes, reflecting an effective tax rate of 19.77.

Stock Price Statistics

Syngen Biotech Co.,Ltd.'s stock has declined approximately -21.42857% over the past 52 weeks. The 50-day moving average sits at 95.00, while the 200-day moving average is 114.55.

Income Statement

Over the trailing twelve months, Syngen Biotech Co.,Ltd. generated 2.12B in revenue and converted that into 279.44M in net income, yielding earnings per share of 10.31. EBITDA reached 349.36M, while operating income came in at 349.36M.

Balance Sheet

Syngen Biotech Co.,Ltd. holds 222.83M in cash and equivalents against 419.26M in total debt, resulting in a net debt position of 27.65M. Total book value stands at 1.42B, with working capital of 514.37M providing operational flexibility.

Cash Flow

Syngen Biotech Co.,Ltd. produced 377.47M in operating cash flow over the past twelve months. After subtracting -65.80M in capital expenditures, free cash flow totaled 311.68M - equivalent to 11.50 per share.

Margins

Syngen Biotech Co.,Ltd. operates with a gross margin of 36.27, reflecting its pricing power and cost economics. The operating margin of 16.45 and net profit margin of 13.16 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Syngen Biotech Co.,Ltd.'s most recent stock split took place on September 19, 2019 with a 50:51 split ratio.

Scores

Syngen Biotech Co.,Ltd. posts an Altman Z-Score of 4.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.